<SEC-DOCUMENT>0001193125-13-281675.txt : 20130703
<SEC-HEADER>0001193125-13-281675.hdr.sgml : 20130703
<ACCEPTANCE-DATETIME>20130703061147
ACCESSION NUMBER:		0001193125-13-281675
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130703
FILED AS OF DATE:		20130703
DATE AS OF CHANGE:		20130703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13950932

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d564027d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 6-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the month of July, 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Novogen Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Translation of registrant&#146;s name into English) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-7 Waterloo
Road, Macquarie Park, NSW, Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Form 20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T
Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if
submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s
&#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to
the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Limited </B>(Registrant) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Andrew Bursill</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Secretary </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date 3&nbsp;July 2013
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g564027txpg3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3&nbsp;July 2013 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Funding Arrangement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen today announced that it has put into place a funding
arrangement with a sophisticated US-based institutional investor, providing it with up to $5 million of working capital over the next 3 years. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key highlights of the transaction are: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">underwrites the funding of the primary goal of Novogen in bringing CS-6 through into the clinic, as well as the secondary goal of identifying a panel
of phenotype-specific anti-cancer drugs for the purpose of personalized chemotherapy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provides funding as required up to $5.0 million; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">staged discretionary funding minimises dilution to existing shareholders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Agreement, the investor will invest up to a maximum of $5 million in Novogen by purchasing up to 5 interest-free convertible securities. The price of each security is a minimum of AU$165,000 and
a maximum of AU$1.0 million by mutual consent. The Investor will also receive options which will expire at the end of three years and have an option exercise price of 130% of the average daily VWAPs per share for the 20 consecutive trading days
immediately prior to 2nd&nbsp;June July 2013. Usual adjustments for reconstructions apply. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The first investment of $1.0 million will be made
immediately by way of a converted security with a face value of AU$1.1 million. Subsequent tranches can be activated 120 days after the previous tranche. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The conversion price for the convertible securities will be, at the Investor&#146;s discretion, either 90% of the average of 3 daily VWAPs per share, as selected by the Investor, during the 20 consecutive
trading days immediately prior to the relevant Conversion Notice Date, or a limited number at 130% of the average of the daily VWAPs per share for the 20 consecutive trading days immediately prior to execution of the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Agreement includes terms that grant Novogen the right to repurchase Convertible Securities for cash and limit the rate that the Investor can dispose
of any shares received on conversion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen has the right to terminate the Agreement at any time by the payment of a modest termination fee
or, alternatively, at no cost if the Company&#146;s share price falls below a specified base price. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr Graham Kelly, Novogen Chairman and CEO, said today, &#147;We welcome the presence of a large
institutional investor on our share register that has a strong track record of investing in early-stage biotech companies. It is a validation of the Company&#146;s pipeline and raises our profile in the US financial market and other players
operating in the US.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;In seeking ongoing funding for our drug development program, we were anxious to minimize shareholder
dilution by taking only that much money that was needed as and when it was needed. This funding arrangement provides Novogen with sufficient capital to fund the next step of bringing CS-6 through into the clinic as the first step in the
Company&#146;s goal of developing CS-6 as the first complete chemotherapy capable of delivering clinically meaningful activity against both differentiated and undifferentiated (stem) cancer cells.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Novogen </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen Ltd is a public
Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol &#145;NVGN&#146;). The Company is based in Sydney, Australia, with an office in New York City, USA, and is focused
on the development of a family of novel anti-cancer drugs based on complete anti-cancer activity against both differentiated cancer cells and their undifferentiated progenitor cells. The Company&#146;s inaugural drug candidate is CS-6. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About CS-6 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CS-6 belongs to a new class
of drug candidates known as Mitochondrial Electron Transfer Inhibitors (METIs) that work by depriving the cancer cell of its main energy source, ATP. CS-6 has had its electronic signature altered to be a potent METI in both differentiated and
undifferentiated cancer cells. CS-6 is being developed in the first instance for the treatment of temozolomide-resistant glioblastoma mutliforme, the main form of primary brain cancer, and late-stage, platinum-refractory ovarian cancer. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Further information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact Dr Graham
Kelly, Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 61 2 9476 0344 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Fax: 61 2 9476 0388 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mobile: (61)&nbsp;0429 854 390 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: <U>Graham.Kelly@novogen.com</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further information is available on the Company&#146;s web site, <U>www.novogen.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g564027txpg3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g564027txpg3.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*0"9`P$1``(1`0,1`?_$`,$````%!0$!````````
M```````#"`D*`0($!0<&"P$```8#`0````````````````$"`P4&!`<("1``
M``8!`P,"`@4%#`L``````0(#!`4&!P`1""$2"3$3(A1!47$R<[%"LB,SD<%R
MPM)#@[,D%1<*\&&AT5)B@J(T%A@1``$"!`,%!`4*`P4)``````$"`P`1!`4A
M$@8Q05%Q!V$B,A/P@:&Q,Y'!\4)2<A0T%0C1@B/A<R0U%F*20X-$)44F%__:
M``P#`0`"$0,1`#\`G\:$"!H0(&A`@:$""U?N#Z;_`$`/H(^FDKGD,H,99]_P
MPVO-<NX+&7DL9<1\@RQ(9IGSC]3LC87>R2Q21\A?J9:KU!7&CLSJ&(FG*S]=
M!D]:$]5U&"Q"[G$A1D44GG4GFL3S)!*N7'U>Z*,YJIJAUA^@5_=14H"FNU4A
M(>N1W'&0WPY,F<I^X>[?M'M'Z-A#U#4?.?=WQ=I3.<P=HX5`T($#0@0-"!`T
M($#0@0-"!`T($#0@0-"!`T($#0@0-"!&""Q#"(=WYP%W$0V`3?=`1$0ZCOT^
MO2,"J1A(#BP"X@Y")@CA!QU"E';NV';J&X=``?4=Q]`T,S8)QQ$&%)!"#B%;
M('OIE-VG'L-V@8=QVZ&'8-@$?KZ?;I0*5#,((G*=AR\8J9<F_:`]QNG0HE$>
MOIM\0>NVCPVG`0HCNS)D(Q3J;)',8#!L8.IM]OI#KT#;KTT@.,X@K!,-E*UM
MJ2P5*,OK`CY)C&(=G^:$I<E!Y+X5Y\@9&5AY!&+R%16MAAGKI@^@+#4YJLWZ
ML2$8_9J)KQLPV4>NUT5DS`KW(@(#\.KMI`,N*6TK81+U'#^,<O?N&:K[=4VW
M4=&5)6A.68PQ!)VC'"<.)>%7RX%YIU57`.=I.-9\I,?0I'C>4W19(9PI<>1-
MNYN4:S)V((W""`4PG6*'PF!0KQ``2.JFA':CLBJ-SSJ?X<_D]/9%SZ3]3/\`
M4]&FVW)8%V;&`)Q6.)[>/';SD'`J0?S@]`^D!]?L$=5V-Y1B"ND&_>H)?O@*
M@F*!1$O=T#XNFP%$?L#1ID?#CC[804J62E*%)*\`>4&]Y#[E`PJ;=![?4OV_
M:(=/LTE9+1S+(`,!*PJ:4'$8$C'YH+!8J8@4XB7<=@[M@Z;]1ZB'3U_U=-*F
MDXI,QQA,T@3DXK&68B7\-D9)3D'N-OL`".XB/3?Z="'M@V[8+.H41^$1$0#<
M=A#X=]NINOIM^322XA'C($X3([03+@-I]D4]PJ?Q&[NO0!VZ;CU`!$=M$7VI
M`3&V#2E2A-,Y`;#]$5]XI@#;NZ]?AZCL`[;B&_3J(?NZ(Y$+&,C*$)453F,/
M3A%1-L`FV4';Z.WUTL*WS!$&2DC!,SR(@H5R;"`=1[MA`!^(!#J.X`(["&DY
M@B:C.1@P#+^D.\-H/IOB\IRCW?&7N#;<.X-RB(`;8P;]!$H[AHNZI&=&R""=
MX!2L[C%/>`@AW;B40]0'H'3?IZ:25-LH!)\9@@5+<+:$GRT[^V![R?\`S_N!
M_*TYY([?E,'F3]DQ$DY/\A>5F%?)[RLS1BRWWJXXQXH)X@NN3,%FLDR\J<SA
M^Y5Z`K=Y6CJRH]/"L7,,9U\^+A-O[J"I@<;]J:@#K6KNEUI=1.%E2ETC8F4S
MPE/A'=^DM):!NO1.TV2^T[-/>+RIQMBM"0'$OHS*;05\%2E+@)1*-Q)E2EYI
MQS2<LX[FFL_1\@P439*U*(G`_OQ\HF5047!0,8R#]DOW(+H&V,@NF8A@`Q1#
M6P*"H3<:,5*$IS+!)]4<2WZQW.Q7E^SUH":^G=4E:92D$&2B.(4F1!AK?PLW
MJ\7_``=R+D[]<[5=Y&-YB9K@HM_;I^2L+Z-AH]W%%80D>XE'#A5E#QY3C[#9
M,011`1[0#?438GZAY+KCIFVE9$N4;3ZU6JS6B]6YNQLI;:=M=.XI($DEQ2.\
M9=IQ)A/EVS!R=\G7*;+/&SC'EJ9X[<1./$JI5<S9PI(=E]R/<"N'3%W5:G+"
M8JC-FJ]8.DD2H*)$!!N=TX,H"K=N:,??J-05YI:1Y;-*W/,4F4R-GIV1?Z.P
M:-Z.Z(H-8:NIF[CK.ZH*V*-T?TV6]SI&/9N.V0CIUW\0EEI%<5MG$KFERQQ]
MG>`;&?PLKD3,$E?:5<YEJ3O2C[9#2#8B#%I**%]HRJ2:J*(&[CMU2@)=/#2S
MK22\S5.^>D3$U;Q$-;>O=#>*]NWZUM-JJ=-+6$K0RP$/-M'`E!EWE`8C9.6&
M,-U<I;MD7RA>,3D+0\F4I"O<W_'MD)A=LA5&,8`BI84Z@2;A[3.P<>@H8&@V
M*F_WU\PT1,H@+Z/(=#N260`+'T[U.7JM;-4C*^VK(0=X^U&A?WC]%J>TV!JZ
M:5=_$:0KZ<U=&K:X$3[S9WYDS&/V09Q$[P_EF]X&R;C[-.+9Q6#O^.+)&76H
MRB)Q!/YV/'O%@]2((`ZA9R/549O4#?`NS<J$'H.MZU].S<:*2`")1Y7V*]5V
MFKTFYT>9-13D9CO'&<?42XW<D:5R(XU8PY,P;I..J&0L<1E_?`LL7:O&38JG
MM40]6-\)%:M+,'C14-P'N;FWUIFX-_@JAQAPR0B<U=GT1Z4:3N!U1;*&KH!G
MJ*U#<D\%+DDC_>P$-`<0N54Q4>//.SREYVM%QF,<7[)]D_P*QP^L<HM",L>4
M>44J%%AZ7"OG1X>(?7VUNDVZR[=$H&%N94^Y0-JE4=VJFZ"HO#I_I!Q00.(!
MD".<=7:PT-27/6=@Z2Z:0A-R13-"I>`[WF+`4XI:AMR(!)GOELC6\?N(O*7R
M+5N,Y.<X^1>9L6T[(J`63$O&O`MH=XT@J[09`@+P4A8)!D`R+AQ*LE"*HD6!
M1\HB<JRZY14!!)BW4-YOJ157)Q;3"L0`92$2FK-<Z)Z4U2]&=+K?2UZZ566H
MKJEM*UJJ$X+2F>U$YC;+<(TG(3#?*OQ/,0Y+\:\\Y6Y!\:*U)1JF<^.^=;(M
M=)&%J+]XBQ6M%0M3I/YMHBS.J5-55(J"S-0R:RP.6X*E(NXIN6G_`"WZ);CU
M`526%&83Q,/Z2U'H?K@ZO2^L:%BUZO=3*DK*=`;:+H3@VZD;9D8#&8AVZ^<U
M\/T+APYYK*2#F5Q*?&L;D.$;HJ)HS,\M.H-4X"H)`H(IMK!(3KQ.-4*81!LO
MWF,`E(.IZINE/2VS]2=5,`9AP5,8#MQC1-KZ:ZAN&OATW:`;OQK2RM2\4I2%
M$J6."0CO#LE#7.%>*G+CR.5&+Y'\S^2^8L(4&_I!8\6\8./4T?'C.MT:1$%X
M%_;K#[2\F_D9>,437("Z:CHZ"A53G2$_L)UZAH:^]TOX^YO.,YU$H0DR`28W
M3J;6^ANCUX<TGT_M]'<;E2?TWZ^J2'`MY/B#:92*4JF-P&``,*BQEXMY3`V7
MZ%D;#?-;EDPJ4!8$)&\8GR'?"Y(JU^K:+=4JU945ED4%XLKIR*8G<"FX5*F!
MBIBF82'))TM@%,YYK50ZM6\$S$HHFH^L[>KK0[07RT6L7)29H?8:"%).P=V7
MMXQH_.#<+O2.%T'(46Z7#'\Y(\@<-UYS8*389.MSI8J<FG;.1;)RL4Y:.0;K
M(GZD,84S"4O<4P!MI.I\XI6T(=4T2M(*DXGEZXR?V[4=OJ=:.*N=/35;+=LJ
M'?+?&9!4D`C#CP@HWA_ASH=.>?D.#WDTRAVY_3$0`Y0$1'>O`)C%WVWWW#UT
MA-BGE7^.J`#+9A[8%5UJ:;2ID:;LB@<R3)HYAV@G88Z;Y#F=BP#XM\YL:5D"
M_FG<7X8KT1#Y&=69TEDA^I!3%9C0GI&UQXLWPV65;D,+IR3VQ544,(AL80UF
M7Q:J"R/FG4I;R4X$F9'(Q"=)DTE^ZN6MRY4K;U#4U.-,4R;,TK(3+?B!(<H2
M'XGN3V5Z?:4>$'*FU2]BO4YCVN\@N-63+1)2$D]R=BJ_0+.SR-:5F99=P^E9
MFG.WCCVR*JG7*B@X1$1!L`FAM-75ZE2FTW$E3RT!:%J/BGCE]4;*Z[:.T]<F
ME]0M!TQIK8W5KHZNF2`!3U""4A02-B3+$[,0=\=4\R5\OE''@66C7>WTG_V3
MF;1*]8352Q2L`,]!ND/[1$3`Q;II_>46J;XC-UNY$PAU*.^G]55=73MT@IQ)
M9J0,.&'H8KW0'3MLU"G4B;FRVZ*.S..HSB<EI."AVX[>R'L?:-_QA_V_R-6_
M.]P'MC0>9O[/I\L,+<;82)LGF@\F<!/1[.6@YK`^+HB:BY%(CAA)1,I&5IA(
M1[QNJ!DUFKQHN9-0@AL8AA`?75)H&$5&I:MIP304R(CIO6U144/0+2%93E27
MDUSJD$'8M.8I(W3G&GX=S$MXWN9<[X];Z^>?_-^=Y>6R=PHM<PMW,X26>N??
MLN'E7ZPAV+_,G$K9+\YV0AP#N?@(*H'5V6XHMJIBFJ%G(?L@3S)_FP$-ZZ:I
M^J.@&.IEI0G_`%31-I8N;:0`K(-CY2.P3)X''9'MO!VDNXXX<HB-1!-XIS1Y
M`E;'$.A'9E8HJ)A`=@V(J(#UVW$-+THYYE/5IG-I-4X.8W2]<1?7I3#6KK*I
M[&E;L]'NE-&7'Y9GMCS/^7_=1++`'(VF2!TD\EU3E5D4<BL52^U*I.7R,>VB
MG4@D?]>)55(QVB3<3%*=!0`V$!#6/HI24)K$+PJ?.Q&^4\.4HFOW2^>J_P!D
MKT2%K<L5.&2,4R&T`[)C#M.^'Z7!@^7.``/40*3M'8W=]'0=MP$>FKNL^5WE
MG".69-N=U1*5$_6VG[L,!\*U(ZS^9?R9V&C$3<X^:T6CU.YK%`CF)D\BH+5]
MG(`;L*=LN<747)HG3,(")B*@)1#<=4JT^8=65M0@_P"'2D###'^,\8ZKZH(*
M?V\:0H[DB5[\Y_R@L8?AE))V'&0PE/"(\?FB\5D_PERC,YKQ/77<AQ-R;8E'
M<.Y8E.Y1PI<9UXHLXQY8Q+W#'U23D55#5YZH((^V;Y(YRJ))^YT!IB]-/I%/
M4JW;./I[(\?.K_3&IL5<Y?+4";"\9NJ&)0>$O<=AYS$*4X(<N;7%>&;-'&:H
MR+ASEVY<F6?&3$4<U.<TJWCN2#%E9)`[-N`@LFT9MBSQ@.3[AU=_JUK_`*HM
MJI6_*I#)54J7:4G;[([#_8DPU?:S]0NO^56-)?63X1E2"@'[R@"D<1#LOEYP
M.UP%X@\;X<IC58U*PK;L#1%N*RW33?0<4N\CY>1=)$#90DM;)1-RH)NW958I
M]P$H:UUJ*@52Z>IF:>88;6F8]/7'8'0_4SFHNN57?:B1N%PIZP-3PQ4DI0!P
M(2)"7`P^UB.=JUCQ?C"<IAFXU2;Q_496K?)G(HV+`/*Y'KQ*2!TSJ)^TC'J)
MD``$2@(;;[AJZTKC512-.-$>64#`<HYLU`Q54]^K6GI>:S5.A:22%%06021O
MQYQQ3GA,U:!X:<I)6Y*LT:^E@O)+=Z9^!#-%E)"L/8Z,:F(K^J46>2KM!)(@
M]3K&*`;CK#O7EHM-5FEWF58<3E(F/[(L_2E#M1U(LJ*0DE5R8)&^06,TAL/=
MG.(W.8JO>T/\NCQT<2#:1<QD/>J?<+,Q`BA%38Y?9*N(PQW1P[E$V"JLLR.0
MX^A%$S>@:H+Z:C_YZRI4\%))&\#.1\D=>VJJM9_=?>&*,S?4S4-LJ,I^=Y0$
M@#OE@.1B5MAVPUFVXNQY:*>Y9NJE/T.G2M978"!FIH)[7V*\:"':``5--L8I
M0+L`D,40$`$!`-C4SK"J=M3<B,B1+AA_;'#>HZ:KH;]6T5<%HK&ZEP.9IYLV
M=4R9\=O;MA.G*OF+$\6;IQAILO1YNWK<FLQM,.Q#Z(E(V-0J+]Z5HHE/RJ;X
MIU)%@F5V`&20V4W+Z]=%6US5*^TP1\4E(YRG$[I;1=1JRCN553/AM%OIDO&8
MF2#,$#UB>_E"&?/>5RKP=KB:"Y6SY3D=A-%JX.F54K5X>;=D;.3(C^W*V<&*
M;M$-C[;#L`CJMZN0IRW,Y7`VX7DS43+83(1MC]L5124O4)YRJ9344J+;4YDJ
M)`4`D;P#CPCI%8XR^4J/FJK(6#R0TF=K+.:@WTU`H\8:I'.)B":/VSB7ADY0
MDJ95BK*1R:C<JX=QDS*`<`';68Q07V:7C4(6RD3/T2D8C;WK+I&\W4IM^EW*
M>L\M0"C4J6`K<H)GQQE./>^8#<WC-Y@F*!B`7&:/N)FV+OM9J_O\0;`(AL`?
M1Z:+4ZGF[#4N#XN1!GS4!$+T*4A'5RQNU!.0U![O`^6O*>S'TPA+/(CB;:LY
M\!>'F;,#J*0_++BQAO$.4L(S4<F`2$Z,91JW(6+';L""4SMG96C0!01/NFHZ
M3!,0[%U-V:NU?B;=35E.)5S#*5H5P,@3AOY'"+II36U)9.IUWTIJ97_I=YKG
MF*L+[R6RI:DH>GN*9]Y7#:<(1YS3Y9U3FEQZ\7V:JZ4L7-N^;N/Z]D>E'$2/
M*'DF&:H-[767J"H^^B1)X;WVG?\`$=FND8=C"8`@KM=$5U%0O[*A=6!+>"")
MX1L/IGHBOT'JS5VGZG_+?T-];+X\+U/-1:6%;,=AEO$2I>TOU!K9,U<8XKS&
M&D>/O&[,U&\I'-?D9:*JC'8>RYC/&U=H%J+-1+Q6<F()*O%EV:T(V<GEHSY8
M6*W:=PF0AP*':([AO6[;;JAF_/5CG@6CVSC=6KM9VN[])-/:1HR?U6WU"UN@
M[`#/$?+'8_(OP\;\P<`N*S7G"<!F?',LVR3@2[D.9H]K.2:X(/8YJ601$BK.
M,LORP,W`@8"D,=);83(EVR;W;/U&WEI,Q5)45((VA0V8\#OXQ`](NHR.GNJD
MU]<V:G3]85,5+!V.-J$IG=-!Q3S(WPG_`,,F!L^<?N-V28#D=2G]$R+;\]W;
M(3B,?/H22<2#>QQE=65G/=KSMW&E*_ETW.Y"F+L)-^P`$-1&C:"LHK8JEN$@
M^7BK9MGQBY_N2U?I#5FL:.XZ-.>QT]O::/\`LK3/N?RX`1SGD!P;Y/8&Y0V;
MFQXZ9&IN)_)*8DS[QOODG_<%.R<Y]T'3F?K\INFTCII\Y$S@Y%5$#MWRJJR"
MW:NX04=K+/<;?<7+Q9T)?><EF:)RI(X@[I?1#VE.I&D=1Z0;T#U-;>+3*LU'
M5)!4XP!@`K:5)`.R4I3S01<N1'F!SC7%L8XFX-0?%^QS38\;/YMRAEZM6.)J
MA7?NMG4S2(F*;"[=O&R?ZQ!15!T=(VP@D<W:8&GZS55R2*5%"A@*$BXIP'+O
MF!A/A&=0:1Z"Z<J1>[[J1R\LMJ\Q-(W3J1,CPH6K'">V4@<03*%J>/G@U5^#
M.'W5+0G'%^R5>IXUUS)DU^@LB\N=S<E$@F;(N57+M""ATU3D:$65464.HJX5
M,*RY]2MJM?Z0%K6%+J'B"H[I]F&`C675#J9<^IE\1=*M`IK72(#-*RD22VT,
M!)(P!(E,[/?"R<A8[IF4:=9L?Y#K,1<Z/<81[7K54IYHF\A9Z'?HG2=LGS50
MHE43.!^XIPV42.!3D$IRE,$^A:VE^8V2%=D:MJZ"DKJ95'5H2ND6)*01-)GQ
M'M[#B,1$83A'X<[]Q>\H]ED'$?/RW#;%3<<T8-M4LN@[C)F[SK%Y7*M3I$@O
M3N7EVQBVDWH+O%6Y069MFJH*=ZIR@]J&I%[51U:Y'\.)2^<\8P^DS;O2ZQZA
MTQ3C,W>JALH<`V-`>"8V2&$OFB2YF/%%-SKB^[XAR)$)3U(R%77U;L48H<4C
MK,)!`Q0<MU@*91K(Q[@J;AHL4.]%TDF<.I=1M72,W&D53JGDBTV.]UVGKO37
M>V.%%SI74N`X_5,\)2P4,%#>#*&/\,T/R?\`C4:+XAH>*H3GIQ;B';S_``N5
MC;TQHN7\>P[QVLY"O.64Z51HLQ;^Z;^S)@Z:I*_$W.@D;V"5-E%VL1+1;\VE
M3X`!B!VR^B.B+[7]&>JZ$:DKZI6GM7A(+R`PI;50N<BX)$`3]1._8(IDS`_D
M2\G\[6Z;R:I$+PKX=PTU'V&WXWAKHUN.8,K+1*Y7#6,E'T7NPCFH"F((BK["
M#-0?F02<KD0.D"Q<M15*#4)+-.U]783/[7'LV1D6O5/2GHW2NW+2;IO^NG6\
MK+JT>6S3E0Q*4[U).^9/(0]#/8'Q?:\*27'J9J+%7$3ZAEQD:G)E,@Q;4]*)
M3BV4<R4#8[=Q&MTDSH."C[J:R95`-W@`ZM)MC+E$J@6),$`2&&`,\.&,<[T>
MKK[2ZI&K6GW4ZA14E[S58J4M1S$!6$QC+EA#*6,L/>43QG@_QK@*J5?G1Q-9
MR#E_1*K-VQM1\O8]8/'"KDT(T</E4FQV9%E1$Y$`?-#'[E$DFHJ&3"M*;O=H
M?*:"F%4RK<592B6R7&<=$W/4/2#JS_W+4U0Y8-;E`#I2WYC+IE+.K<"=L\%=
MI$%Y*K?D/YZYTX>6*]<+H_C)CCCAGN`RW,3]OS)7;!-RC-F9@$HT:0<2U,NN
MLF@U$S<"I_K#]#'3#J+2UZAN-<P[5T::=#"\^;.%3PE*0E`M]1TKZ::8O-):
MKPN[7:YTH8"4M%"$2).:>/&4B>V%I^7#CQFCD]Q:A\?8,J"%TO<9F7&=X+"N
MYZ(K":D159%R_D5E)6<<M621R@8@`4#&.8Q_A*;8=I35%(_6T2!0L)J'$NI5
MD4K*,"9F?9&O.B6J++I35U36W^J-';G*-UH+0V7%`N@"64;9XXRPCQJ/)KRS
MI(D2-XT,;G*0A2=W_P!854`[2%#M+\,(;M$>T`WZ[#]>L0W#43"4@6YMMJ4C
M)P*D.P;3$H[HWHN]5+?_`-35"`HDS-,LGUB0$=6YE8^S]RA\:V6,>DQ<SKG(
M?*6)XYJOB1K<HB2C8:X*3,0]?5M"ZNS,(A^U:$:*"5T;VTU-OHW#4Q=&G;A9
MG&%IRNNMR([1(B7#$17.G]XTUHSJU1W9^J+]DIZHD.J04YD!L@$)W$DRA7?'
M.K3-(X_X,I5F:$C[/3<18YJMA9)+H.2QT[`U&*C)5J1RW,HW<_+2#10H*)F%
M,X!N41`=9-(AVFI&$/;0@)/J&Z*/JZJ:N.I*VY4Y5^%J:QU3>..1:RH$]HW&
M(]'-GQ?YUB^:F.<J\8::K9,$9/SWC;.>6J1%24+&,,;Y1J-C:-[-:T(V5>,`
M4B[/7)-VZ`&@&.#CYA(Q.T6_;1+[INM<O3-;1#_!E84H;@1O'".M^EW7"P.=
M.+EIK6"P+S3VQREIGCXW$$$ALJ,R9&0]0,2C^\OU_P"PW^[6Q,PX^^.+XU2O
MW@_"0_K3:=^L8)K\P8N<?M$?L/\`E#1?6/*`GX'\_P`\!'\[[0_1+K$=\`YQ
MBH_XO]X8"GW#_B%UE(^#ZHS7?&W]P^Z"Q]#_`(A_W]8U+XE<_GAM'P5^OWQ<
MC_-?AI_ICJ21X3SA2OS_`/RHV3C]DI^&?\@:QX2OPGE&@1]%/Q@_JC:)K\L?
M7#3'P6?Y?=&Q-]XW\#^.&CI=D(_\DC[@C!5^\3\13]$-.O\`C3SB4'YI/*#6
MWW2?PE_W]&?S*ON)^:,`^!7-<9'YI_\`I_(&@?$.<(_Z!OF/>8*2_:(_A?OJ
M:QZO="ZC\RGE!YON)_TOY`TTSL/*'']AYQ<;T)_!1_3+I[=Z<(PU_FO4(N6_
M8F_T_.'08^((R*CZGWD^\1KS_P#B_P!"?](FEUFT?>$'<O&KE\XC);?SGXO\
D0-)7X(6]\)B"'WW3_C*?U6G5>$<OXQ@U?PT_W@C9Z;B6C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
